| vandetanib plus docetaxel versus placebo plus docetaxel | |||
| Heymach, 2007 | vandetanib (100 or 300 mg/d) plus docetaxel (75 mg/m2 intravenous infusion every 21 days) versus placebo plus docetaxel | previously treated non small-cell lung cancer | |
| abemaciclib versus erlotinib | |||
| JUNIPER, 2018 NCT02152631 | 200 mg of abemaciclib orally twice daily versus 150 mg of erlotinib | patients with stage IV NSCLC with a detectable KRAS mutation who progressed after platinum-based chemotherapy and who may have received 1 additional systemic therapy | open-label |
| afatinib versus cisplatin-based chemotherapy | |||
| LUX-LUNG 3, 2015 | versus | EGFR mutation-positive lung adenocarcinoma | |
| LUX-LUNG 6, 2015 | versus | EGFR mutation-positive lung adenocarcinoma | |
| Aflibercept and Docetaxel versus Docetaxel | |||
| Ramlau, 2012 | versus | platinum-pretreated patients with advanced or metastatic nonsquamous non-small-cell lung cancer | double-blind |
| alectinib versus chemotherapy | |||
| ALUR, 2018 NCT02604342 | oral alectinib at a dose of 600 milligrams (mg) twice daily versus chemotherapy with either pemetrexed (500 milligrams per square meter [mg/m^2] of body surface area) or docetaxel (75 mg/m^2) intravenously. | ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib | |
| alectinib versus crizotinib | |||
| ALEX, 2017 NCT02075840 | alectinib 600 mg orally (four 150 mg capsules) BID versus Crizotinib | patients with stage IIIB or IV, ALK-positive NSCLC who had not received prior systemic therapy | open label USA |
| atezolizumab versus docetaxel | |||
| OAK, 2016 NCT02008227 | atelozumab versus docetaxel | Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy | open label Follow-up duration: minimum 19 months |
| POPLAR Phase 2 atezolizumab, 2016 NCT01903993 | Atezolizumab versus docetaxel 75 mg/m(2) once every 3 weeks | patients with locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Th | open label 13 countries in Europe and North America |
| atezolizumab + bevacizumab versus bevacizumab (on top platinum-based CT) | |||
| IMpower150 (Teff), 2018 NCT02366143 | atezo + bev + C + P
versus bev + C + P | chemotherapy-naïve patients with Stage IV non-squamous non-small cell lung cancer and expression of a tumour T-effector gene signature (Teff) and EGFR et ALK negative (wild type) | open label |
| IMpower150 (WT), 2018 NCT02366143 | atezo + bev + C + P; versus bev + C + P | wild type chemotherapy-naïve patients with Stage IV non-squamous non-small cell lung cancer (EGFR et ALK negative) | open label |
| bevacizumab versus platinum based CT | |||
| Sandler, 2006 | PCp +bev versus PCp | ||
| Johnson, 2004 | PCp +bev versus PCp | ||
| Nishio, 2009 | PCp +bev versus PCp | ||
| Herbst, 2007 | D/M +bev versus D/M | ||
| bevacizumab + erlotinib versus erlotinib alone | |||
| Herbst, 2011 | erl+bev versus erl | ||
| bortezomib and pemetrexed versus pemetrexed | |||
| Scagliotti, 2010 | Pemetrexed plus Bortezomib versus pemetrexed | ||
| cediranib versus carboplatin and paclitaxel | |||
| Laurie, 2014 | cediranib 20mg daily to carboplatin/paclitaxel versus | patients with advanced non-small cell lung cancer | double-blind |
| Goss, 2010 | versus | initial therapy for advanced non-small-cell lung cancer | double-blind |
| cediranib versus gemcitabine and carboplatin | |||
| Dy, 2013 | versus | first-line therapy in advanced non-small-cell lung cancer | |
| ceritinib versus chemotherapy | |||
| ASCEND-4, 2017 NCT01828099 | oral ceritinib 750 mg/day versus platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 weeks for four cycles followed by maintenance pemetrexed | untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC | open-label |
| ceritinib versus pemetrexed or docetaxel | |||
| ASCEND 5, 2017 NCT01828112 | Oral LDK378 750 mg once daily versus pemetrexed or docetaxel | patients previously treated with chemotherapy (platinum doublet) and crizotinib | USA |
| cetuximab versus CT | |||
| Lynch, 2010 | cetuximab (400 mg/m(2) on day 1, 250 mg/m(2) weekly) was administered until progression or unacceptable toxicity plus taxane/carboplatin versus paclitaxel (225 mg/m(2)) or docetaxel (75 mg/m(2)), at the investigator's discretion, and carboplatin (area under the curve = 6) on day 1 every 3 weeks for < or = six cycles | chemotherapy-naïve patients with stage IIIB (pleural effusion) or IV NSCLC, without restrictions by histology or epidermal growth factor receptor expression | open-label |
| cetuximab versus CT alone | |||
| Butts, 2007 | cetuximab (400 mg/m2 i.v versus cisplatin (75 mg/m2 i.v., every 3 weeks) or carboplatin (area under the concentration-versus-time curve of 5 intravenously [i.v.], every 3 weeks), and gemcitabine (1,250 or 1,000 mg/m2 i.v., days 1 and 8) | chemotherapy-naïve patients with recurrent/metastatic NSCLC (stage IV or stage IIIB with malignant pleural effusion) | |
| cetuximab + CT versus CT alone | |||
| FLEX (Pirker), 2009 NCT00148798 | Cetuximab-at a starting dose of 400 mg/m(2) intravenous infusion over 2 h on day 1, and from day 8 onwards at 250 mg/m(2) over 1 h per week-was continued after the end of chemotherapy until disease progression or unacceptable toxicity + CT versus cisplatin 80 mg/m(2) intravenous infusion on day 1, and vinorelbine 25 mg/m(2) intravenous infusion on days 1 and 8 of every 3-week cycle) for up to six cycles | chemotherapy-naive patients with advanced EGFR-expressing histologically or cytologically proven stage wet IIIB or stage IV non-small-cell lung cancer | open-label |
| Rosell, 2008 | cetuximab treatment (initial dose 400 mg/m(2), followed by 250 mg/m(2) weekly thereafter) + same CT versus for a maximum of eight cycles, patients received three-weekly cycles of cisplatin (80 mg/m(2), day 1) and vinorelbine (25 mg/m(2) on days 1 and 8) alone | first-line therapy in EGFR-expressing advanced non-small-cell lung cancer | |
| crizotinib versus chemotherapy | |||
| Shaw, 2013 NCT00932893 | crizotinib (250 mg) twice daily versus intravenous chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 weeks | patients with locally advanced or metastatic ALK-positive lung cancer who had received one prior platinum-based regimen | open-label |
| PROFILE 1014, 2014 NCT01154140 | oral crizotinib, at a dose of 250 mg twice daily versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin | patients with advanced ALK-positive nonsquamous NSCLC who had received no previous systemic treatment for advanced disease | open-label Follow-up duration: 16.7 months |
| dacomitinib versus gefitinib | |||
| ARCHER 1050, NCT01774721 | dacomitinib versus gefitinib | Patients (pts) with newly diagnosed stage IIIB/IV/ recurrent NSCLC harboring an EGFR- activating mutation (exon 19 del or exon 21 L858R mu +/- exon 20 T790M mu) | |
| Docetaxel plus nintedanib versus docetaxel plus placebo | |||
| Reck, 2014 NCT00805194 | versus | patients with previously treated non-small-cell lung cancer | double-blind |
| durvalumab versus placebo | |||
| PACIFIC, 2017 NCT02125461 | Durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) every 2 weeks for up to 12 months, administered 1 to 42 days after the patients had received chemoradiotherapy versus placebo | patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy | double-blind |
| durvalumab + tremelimumab versus Standard of Care | |||
| ARCTIC PD-L1 negative, 2018 NCT02352948 | combination of MEDI4736 (durvalumab) plus tremelimumab versus Standard of Care | patients with PD-L1 negative Locally Advanced or Metastatic Non Small Cell Lung Cancer who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC | |
| enzastaurin plus pemetrexed versus pemetrexed | |||
| Chiappori, 2010 | Pemetrexed plus enzastaurin versus pemetrexed | ||
| erlotinib versus Platinum-based CT | |||
| OPTIMAL , NCT00874419 | oral erlotinib (150 mg/day) until disease progression or unacceptable toxic effects versus up to four cycles of gemcitabine plus carboplatin | Patients older than 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) | open-label |
| EUTRAC, NCT00446225 | oral erlotinib 150 mg per day versus 3 week cycles of standard intravenous chemotherapy of cisplatin 75 mg/m(2) on day 1 plus docetaxel (75 mg/m(2) on day 1) or gemcitabine (1250 mg/m(2) on days 1 and 8). | adults (> 18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending ¡Ý 6 months before study entry was allowed) | open-label |
| TITAN, NCT00556322 | erlotinib 150 mg/day versus chemotherapy (standard docetaxel or pemetrexed regimens, at the treating investigators' discretion) until unacceptable toxicity, disease progression, or death | second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis | open-label |
| erlotinib + Platinum-based CT versus Platinum-based CT | |||
| TRIBUTE (Herbst), | erlotinib 150 mg/d combined with up to six cycles of carboplatin and paclitaxel, followed by maintenance monotherapy with erlotinib versus placebo combined with up to six cycles of carboplatin and paclitaxel, followed by maintenance monotherapy with erlotinib | patients with good performance status and previously untreated advanced (stage IIIB/IV) NSCLC | |
| Gatzemeier , | Erl 150 mg/day plus (Gem 1,250 mg/m2 D1,8 and Cis 80 mg/m2 D1)*6 cycles versus Gem 1,250 mg/m2 D1,8 and Cis 80 mg/m2 D1)*6 cycles | first-line treatment for advanced non-small-cell lung cancer | |
| Mok , | Erl 150 mg/day plus (Gem 1,250 mg/m2 D1,8 and either Cis75 mg/m2 D1 or Car AUC = 5, D1) versus Gem 1,250 mg/m2 D1,8 and either | first-line treatment for advanced non-small-cell lung cancer | |
| SATURN (Cappuzzo), NCT00556712 | Erl 150 mg/day plus select one of seven standard chemotherapy regimens versus Cis75 mg/m2 D1 or Car AUC = 5, D1 | maintenance treatment in advanced non-small-cell lung cancer | |
| Boutsikou, | Erl 150 mg/day plus (Doc 100 mg/ m 2 and Car AUC = 5.5 q28d*4) versus Doc 100 mg/m2 and Car AUC = 5.5 q28d*4 | first-line treatment of patients with NSCLC | |
| Lee , NCT00550173 | Erl 150 mg/day plus Pem 500 mg/ m 2 D1 q21d versus Pem 500 mg/m2 D1 q21d | second-line treatment for never-smokers with non-squamous non-small cell lung cancer | |
| Stinchcombe, | Erl 150 mg/day plus Gem 1,200 mg/m2 D1,8 q21d versus Gem 1,200 mg/m2 D1,8 q21d | elderly patients (age ¡Ý70 years) with stage IIIB or IV non-small cell lung cancer | |
| FASTACT-2 (Wu) , NCT00883779 | Erl 150 mg/day plus Gem 1,250 mg/m2 D1,8, six cycles and Car AUC = 5 or Cis 75 mg/ m 2,D1 versus Gem 1,250 mg/m2, d1,8, six cycles and Car AUC = 5 or Cis 75 mg/ m 2,D1 | patients with untreated stage IIIB/IV non-small-cell lung cancer | |
| gefitinib versus carboplatin-paclitaxel | |||
| NEJ002, 2013 | versus | chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations | |
| Maemondo, 2010 UMIN-CTR C000000376 | versus | patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy | |
| IPASS (Mok), 2009 NCT00322452 | versus | previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers | |
| gefitinib versus carboplatin/paclitaxel | |||
| IPASS, | versus | previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma | |
| gefitinib versus cisplatin plus docetaxel | |||
| WJTOG3405 (Mitsudomi), 2010 | versus | patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor | |
| gefitinib versus continued platinum-doublet chemotherapy | |||
| WJTOG0203 (Takeda), 2010 | versus | Japanese patients with advanced non-small-cell lung cancer | |
| gefitinib versus docetaxel | |||
| ISTANA (Lee), 2010 | versus | previously treated advanced nonsmall-cell lung cancer | |
| V-15-32 (Maruyama), 2008 | versus | previously treated advanced nonsmall-cell lung cancer | |
| INTEREST (Kim), 2008 | versus | previously treated advanced nonsmall-cell lung cancer | |
| SIGN (Cufer), 2006 | versus | previously treated advanced nonsmall-cell lung cancer | |
| IFCT-0301 study (Morère), 2010 | versus | patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 | |
| gefitinib versus gefitinib | |||
| Kris, 2003 | versus | Patients either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens | double blind |
| gefitinib versus gemcitabine and cisplatin | |||
| First Signal, | gefitinib (250 mg daily) versus GP chemotherapy (gemcitabine 1,250 mg/m(2) on days 1 and 8; cisplatin 80 mg/m(2) on day 1 every 3 weeks, for up to nine courses | first-line therapy of never-smokers with adenocarcinoma of the lung | |
| gefitinib versus placebo | |||
| NCIC CTG BR19 (Goss), 2013 | gefitinib 250 mg per day versus placebo | completely resected non-small-cell lung cancer | double-blind |
| INFORM; C-TONG 0804, 2012 NCT00770588 | versus | maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer | |
| EORTC 08021/ILCP 01/03, 2011 NCT00091156 | versus | patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy | |
| Goss, 2009 | versus | chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status | |
| SWOG S0023 (Kelly), 2008 | versus | inoperable stage III non-small-cell lung cancer | |
| ISEL, 2006 | versus | patients of Asian origin with refractory advanced non-small cell lung cancer | |
| Tsuboi, 2005 | versus | patients with completely resected non-small cell lung cancer | |
| gefitinib versus vinorelbine | |||
| INVITE (Crinò), 2008 NCT00256711 | versus | chemotherapy-naive elderly patients with advanced non-small-cell lung cancer | |
| gefitinib paclitaxel and carboplatin versus paclitaxel and carboplatin | |||
| INTACT 2, 2004 | gefitinib plus paclitaxel and carboplatin versus paclitaxel 225 mg/m(2) and carboplatin area under concentration/time curve of 6 mg/min/mL (day 1 every 3 weeks) | chemotherapy-naive patients with advanced NSCLC | double-blind |
| gefitinib + gemcitabine/cisplatin versus placebo + gemcitabine / cisplatin | |||
| INTACT 1., | gefitinib 500 mg/d, gefitinib 250 mg/d, versus placebo | chemotherapy-naive patients with unresectable stage III or IV NSCLC | double blind |
| ipilimumab + chemotherapy versus placebo + chemotherapy | |||
| Reck, 2016 NCT01450761 | ipilimumab 10 mg/kg plus etoposide and platinum (cisplatin or carboplatin) versus placebo plus etoposide and platinum (cisplatin or carboplatin) | patients with newly diagnosed extensive-stage disease SCLC | double-blind |
| Govindan, 2017 NCT01285609 | ipilimumab 10 mg/kg + paclitaxel and carboplatin versus placebo + paclitaxel and carboplatin | Patients with stage IV or recurrent chemotherapy-naïve squamous NSCLC | double-blind |
| phase 2 (phased ipilimumab), 2012 | concurrent ipilimumab (four doses of ipilimumab plus paclitaxel and carboplatin followed by two doses of placebo plus paclitaxel and carboplatin) or phased ipilimumab (two doses of placebo plus paclitaxel and carboplatin followed by four doses of ipilimum versus paclitaxel (175 mg/m(2)) and carboplatin (area under the curve, 6) | Patients with chemotherapy-naive non-small-cell lung cancer | double-blind |
| matuzumab plus pemetrexed versus pemetrexed | |||
| Schiller, 2010 | Pemetrexed plus matuzumab versus pemetrexed | ||
| nivolumab versus docetaxel | |||
| CheckMate 017, 2015 NCT01642004 | Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression versus Docetaxel 75 mg/m2 solution intravenously every 3 weeks until documented disease progression | patients with advanced SQ NSCLC who fail platinum-based doublet chemotherapy | open |
| CheckMate 057, 2015 NCT01673867 | Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression versus Docetaxel 75 mg/m² concentrate for solution for intravenous infusion every 3 weeks until documented disease progression | patients with advanced nonsquamous nonsmall cell lung cancer (NSCLC) who had progressed on platinum-doublet chemotherapy | open |
| nivolumab versus platinum-based CT | |||
| CheckMate 026, 2016 NCT02041533 | Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression versus platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). | patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 at >5% (>1%???). Patients with EGFR activating mutations and ALK translocations, which are sensitive to targeted therapy, were excluded. | open design |
| nivolumab + CT versus platinum-based CT | |||
| CheckMate 227 (nivolumab + CT), 2018 NCT02477826 | Nivolumab + chemotherapy versus chemotherapy | Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer <1% tumor PD-L1 expression | No masking |
| nivolumab + ipilimumab versus platinum-based CT | |||
| CheckMate 227 (High Tumor Mutational Burden), 2018 NCT02477826 | nivolumab plus ipilimumab versus chemotherapy | patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy and high tumor mutational burden (>=10 mutations per megabase), irrespective of PD-L1 expression level | No masking |
| osimertinib versus placebo | |||
| FLAURA, 2017 NCT02296125 | osimertinib (AZD9291) (80 mg or 40 mg orally, once daily) versus first-line standard-of-care treatment erlotinib or gefitinib | previously untreated patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation–positive non–small cell lung cancer | double-blind |
| osimertinib versus platinum-based therapy plus pemetrexed | |||
| AURA 3, 2017 NCT02151981 | oral osimertinib (at a dose of 80 mg once daily) versus intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles | patients with EGFR T790M mutation-positive, locally-advanced or metastatic NSCLC, whose disease had progressed after 1st-line EGFR tyrosine kinase inhibitor (TKI) therapy. | |
| paclitaxel 80mg/m2 versus m2docetaxel 36 mg/ | |||
| Esteban, 2003 | paclitaxel 80 mg/m2 as a 1 h weekly infusion for 6 weeks
followed by a 2-week rest versus docetaxel 36 mg/m2 as a 1 h weekly infusion for 6 weeks followed by a 2-week rest. | patients with NSCLC previously treated with platinum-based chemotherapy | |
| pazopanib versus pemetrexed | |||
| Scagliotti, 2013 | pazopanib in combination with pemetrexed versus | first-line treatment of patients with advanced-stage non-small-cell lung cancer | open-label |
| pembrolizumab versus platinum-based CT | |||
| Keynote 024, 2015 NCT02142738 | Pembrolizumab (200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles or until documented PD
versus standard of care (SOC) platinum-based chemotherapies | previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene | open label Follow-up duration: 11.2 months (median) |
| Keynote 042 (>=1%), 2018 NCT02220894 | pembrolizumab 200 mg every 3 wk for 35 cycles or until disease progression, intolerable toxicity versus investigator's choice of carboplatin plus paclitaxel or carboplatin plus pemetrexed for a maximum of 6 cycles | Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer | open label Follow-up duration: 12.8-mo median 28 countries in Asia, Canada, Europe, and South America |
| Keynote 042 (>=20%), 2018 NCT02220894 | pembrolizumab
versus SOC Treatment (Platinum-based Chemotherapy) | Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer | open label Follow-up duration: 12.8-mo median china |
| Keynote 042 (>=50%), 2018 NCT02220894 | pembrolizumab
versus SOC Treatment (Platinum-based Chemotherapy) | Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer | open label Follow-up duration: 12.8-mo median china |
| pembrolizumab + platinum-based CT versus platinum-based CT | |||
| Keynote 189, 2018 NCT02578680 | pemetrexed
and a platinum-based drug plus 200 mg of pembrolizumab, followed by pembrolizumab for up to a total of
35 cycles plus pemetrexed maintenance therapy versus pemetrexed and a platinum-based drug plus placebo every 3 weeks for 4 cycles, followed by placebo | participants with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease and without sensitizing EGFR or ALK mutations | double-blind Follow-up duration: 10.5 mo median |
| KEYNOTE-021 phase 2, 2016 NCT02039674 | 24 months treatment with pembrolizumab (200mg every three weeks)+ CT versus four cycles of carboplatin and pemetrexed (500 mg/m2 every three weeks) | patients with stage IIIB/IV, chemotherapy-naive, nonsquamous non-small-cell lung cancer | open design |
| pembrolizumab 10mg versus docetaxel | |||
| Keynote 010 10mg, 2015 NCT01905657 | pembrolizumab
10 mg/kg
versus docetaxel 75 mg/m² every 3 weeks | patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells | open-label |
| pembrolizumab 2mg versus docetaxel | |||
| Keynote 010 2mg, 2015 NCT01905657 | pembrolizumab
2 mg/kg versus docetaxel 75 mg/m² every 3 weeks | patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells | open-label |
| pembrolizumanb + CT versus platinum-based CT | |||
| Keynote 407, 2018 NCT02775435 | pembrolizumab + carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) versus carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) | adults with first line metastatic squamous non-small cell lung cancer | open-label Follow-up duration: 7?7 mo (median) |
| pemetrexed versus bortezomib | |||
| Scagliotti (pemetrexed vs bortezomib), 2010 | pemetrexed versus bortezomib | ||
| pemetrexed versus docetaxel | |||
| Chen, 2008 | versus | ||
| Hanna, 2004 | pemetrexed 500 mg/m(2) intravenously (i.v.) day 1 with vitamin B(12), folic acid, and dexamethasone versus docetaxel 75 mg/m(2) i.v. day 1 with dexamethasone every 21 days | patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy | |
| Li, 2012 | pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone versus docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone | patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks | |
| Sun, 2013 NCT00391274 | pemetrexed (500 mg/m(2); on Day 1 of each 21-day cycle versus docetaxel (75 mg/m(2) on Day 1 of each 21-day cycle | second-line therapy for Chinese patients with locally advanced or metastatic non-small cell lung cancer | open-label |
| pemetrexed plus carboplatin versus docetaxel plus carboplatin | |||
| Jose, 2011 | carboplatin (area under the curve = 5 mg/ml × min) and pemetrexed (500 mg/m(2)) 21-day cycle (maximum of six cycles). versus docetaxel (75 mg/m(2)). | first-line treatment for advanced, nonsquamous non-small cell lung cancer | |
| Socinski, 2010 NCT00308750 | pemetrexed 500 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to 6 cycles versus docetaxel 75 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to six cycles | Patients with stage IIIB (with pleural effusion) or IV non-small cell lung cancer and performance status 0 or 1 | |
| pemetrexed plus carboplatin versus pemetrexed | |||
| Smit, 2009 | Pemetrexed plus carboplatin versus pemetrexed | ||
| ramucirumab + docetaxel versus docetaxel alone | |||
| REVEL, 2014 NCT01168973 | versus | patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen | double-blind USA |
| sorafenib versus placebo | |||
| Scagliotti, 2010 | up to six 21-day cycles of carboplatin area under the curve 6 and paclitaxel 200 mg/m(2) (CP) on day 1, followed by sorafenib 400 mg twice a day on days 2 to 19 versus | chemotherapy-naïve patients with unresectable stage IIIB or IV non-small-cell lung cancer | |
| sorafenib and erlotinib versus erlotinib | |||
| Spigel, 2011 | versus | previously treated advanced non-small-cell lung cancer | |
| sunitinib versus erlotinib | |||
| Groen, 2013 | sunitinib 37.5 mg/day plus erlotinib 150 mg/day continuously in 4-week cycles versus placebo plus erlotinib | second-line treatment of metastatic non-small-cell lung cancer | double-blind |
| sunitinib versus pemetrexed | |||
| Heist CALGB 30704 (Alliance): , 2014 | versus | second-line treatment of advanced non-small-cell lung cancer | |
| Sunitinib plus erlotinib versus erlotinib | |||
| Scagliottia, 2012 | versus | patients with previously treated advanced non-small-cell lung cancer | |
| Vandetanib versus gefitinib | |||
| Natale, 2011 | once-daily vandetanib 300 mg versus gefitinib 250 mg | patients with advanced non-small-cell lung cancer | double-blind |
| Vandetanib versus placebo | |||
| Lee ZEPHYR, 2012 | vandetanib 300 mg/d versus placebo | patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor | |
| vandetanib plus pemetrexed versus pemetrexed | |||
| De Boer, 2011 | Vandetanib plus pemetrexed versus pemetrexed | ||
| weekly docetaxel versus 3-weekly docetaxel | |||
| DISTAl 01 (Gridelli) , 2004 | versus | patients with advanced NSCLC patients, < or =75 years, ECOG PS < or =2 | |
| Camps , | docetaxel 36 mg/m(2) given weekly (1W arm) for 6 weeks followed by 2 weeks of rest versus docetaxel 75 mg/m(2) administered every 3 weeks | ||
| Schuette , | versus | ||
| Gervais , | versus | ||
| Lai , | versus | ||
| Chen , | versus | ||
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
